Company & Sponsor Intelligence

Noven Therapeutics

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed3

Countries1

Therapeutic footprint

adhd

Indexed studies

NCT00501293Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
adhd · United StatesPHASE3

NCT00444574Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD
adhd · PHASE3

NCT00466791Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
adhd · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →